Isomorphic Labs Raises $2.1 Billion While Anduril Closes $5 Billion Funding Round

Isomorphic Labs and Anduril announced major funding rounds within the last 24 hours. Isomorphic Labs said it raised $2.1 billion in a Series B round. Anduril stated it closed a $5 billion Series H at a $61 billion valuation. Thrive Capital led both rounds.

Andreessen Horowitz additionally led Anduril's round. The announcements highlight continued investor interest in companies applying advanced technologies to complex technical challenges.

Both companies operate in sectors transformed by recent AI advances. Isomorphic Labs builds on work from Google DeepMind's AlphaFold, which won the 2024 Nobel Prize. The technology has made biological systems more legible to computational approaches.

Anduril develops autonomous systems and weapons. These capabilities rely on technologies that would have been unavailable 20 years ago. Neither company describes itself primarily as an AI company despite using such tools.

Hassabis told Fortune that Isomorphic Labs prioritizes results over specific algorithms. "On the Isomorphic side, we care about the outcome," Hassabis said. "First and foremost, it’s about curing diseases or making a breakthrough on a particular property we care about.

We don’t care so much about the algorithm that got us there, right? " — Demis Hassabis (@FortuneMagazine) Hassabis added that while AGI carries high stakes, pharmaceutical breakthroughs depend on measurable outcomes rather than the underlying methods.

Anduril faces similar pressure to demonstrate effectiveness.

Anduril has systems deployed in the Middle East.

The company must deliver working results in operational environments. Anduril CEO Brian Schimpf shared an investor letter outlining the company's approach. "In our new world, the victors will be those who are best suited to deliver mass and apply advanced technologies to their future force," Schimpf writes.

The letter emphasizes building at scale, deploying superior software, and moving with the speed of a technology company. Both companies have reached points where future success will be measured by concrete results in their respective fields. Isomorphic Labs aims to advance drug discovery and disease treatment.

Anduril seeks to provide effective defense systems. The rest of today's Term Sheet newsletter included additional venture capital deals in cybersecurity, defense technology, sales platforms, treasury management, construction software, health care, finance, breathwork applications, simulated biology, and supply chain technology.

Private equity, exit, fund, and personnel announcements were also reported.